Venus Medtech (Hangzhou), Inc. provides transcatheter heart valve medical device. It engages in the research and development of cardiac intervention system for heart diseases. The company offers pre-implanted invasive heart valve systems such as transcatheter artery and pulmonary artery valve systems, and delivery catheter systems. The company was founded on July 3, 2009 and is headquartered in Hangzhou, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company